Table 2 Immune check point inhibitors, Treatment response in solid cancer
Total | ATB | no ATB | p value | Total | ATB | no ATB | p value | ||
|---|---|---|---|---|---|---|---|---|---|
CR | 0 | 0 | 0 | 0.034 | OR | 44 (21%) | 12 (14%) | 32 (26%) | 0.038 |
PR | 44 (21%) | 12 (14%) | 32 (26%) | nOR | 166 (79%) | 74 (86%) | 92 (74%) | ||
SD | 83 (39.5%) | 32 (37%) | 51 (41%) | DC | 127 (60%) | 44 (51%) | 83 (67%) | 0.022 | |
PD | 83 (39.5%) | 42 (49%) | 41 (33%) | nDC | 83 (40%) | 42 (49%) | 41 (33%) | ||
Total | 210 | 86 | 124 | Total | 210 | 86 | 124 |